Background: Several studies optimized the warfarin dose based on CYP2C9*2, CYP2C9*3, VKORC1 -1639 G > A, CYP4F2 V433M. But, the information on the rare variants is lacking. In this study, we have explored the prevalence of common and rare pharmacogenetic determinants of warfarin and determined their damaging nature.
Methods: We have analyzed 2000 healthy adults using the Infinium global screening array (GSA) for 15 pharmacogenetic determinants of warfarin. In addition, we have elucidated the impact of these variants on protein function, stability, dynamics, evolutionary preservation, and ligand binding propensity.
Results: The GSA Analysis has revealed that CYP4F2 V433M (MAF: 39.425%), VKORC1 -1639 G > A (MAF: 20.5%), CYP2C9*3 (MAF:9.925%), and CYP2C9*2 (MAF:4.575%) are common, while CYP2C9*14 (MAF: 1.475%), CYP2C9*4 (0.175%), CYP2C9*5 (0.125%), and CYP2C9*11 (0.125%) are rare. Position-specific evolutionary preservation (PSEP) analysis has revealed that CYP2C9*4 is possibly damaging, while CYP2C9*5, CYP2C9*11, and CYP2C9*14 are probably damaging. CYP2C9*4 has high thermolability (-10.14 kcal/mol). Among the rare CYP2C9 variants, CYP2C9*4 and CYP2C9*11 exert destabilizing effects and may have increased molecular flexibility, while CYP2C9*5 and CYP2C9*14 exert stabilizing effects and may have decreased molecular flexibility. DNase I footprint analysis has revealed the loss of the E-box consensus sequence due to VKORC1 -1639 G > A polymorphism.
Conclusion: CYP2C9*2, CYP2C9*3, VKORC1 -1639 G > A and CYP4F2 V433M are common; CYP2C9*4, CYP2C9*5, CYP2C9*11, and CYP2C9*14 variants are rare in Indian subjects. All the CYP2C9 variants are found to be damaging. DNase I footprint analysis provided the mechanistic rationale for the association of VKORC1 -1639 G > A with warfarin sensitivity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s43440-021-00297-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Accuracy of an internationally validated genetic-guided warfarin dosing algorithm compared to a clinical algorithm in an Arab population.
Curr Probl Cardiol
December 2024
College of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar. Electronic address:
Article Synopsis
- The study aimed to explore how specific genetic variations (CYP2C9*2, *3, VKORC1-1639 G>A, and CYP4F2*3) affect warfarin dosing in an Arab population and to compare the effectiveness of genetic versus clinical dosing algorithms during warfarin initiation.
- Involving 130 Arab patients, the research involved calculating initial warfarin doses using a clinical algorithm and subsequently using genetic data to determine more accurate dosing after a month.
- Results indicated that genetic variations significantly influenced the required warfarin dose, with genetic dosing algorithms providing more accurate dose estimates than clinical methods based on a lower median absolute error.
Optimisation of warfarin-dosing algorithms for Han Chinese patients with CYP2C9*13 variants.
Eur J Clin Pharmacol
October 2023
Cardiovascular Department, Beijing Hospital, National Centre of Gerontology, Beijing, 100730, China.
Article Synopsis
- Existing pharmacogenetic algorithms do not fully account for warfarin dose variability in all patients, particularly in those from the Han Chinese population with the CYP2C9*13 variant.
- This study involved 971 Han Chinese patients with atrial fibrillation and analyzed the impact of the CYP2C9*13 variant on their warfarin maintenance dose, revealing that standard dosing algorithms often overpredict necessary doses for these variant carriers.
- The findings suggest that adjusting warfarin dosing algorithms to include the CYP2C9*13 variant leads to more accurate dose predictions, enhancing both efficacy and safety in warfarin treatment for these patients.
Warfarin pharmacogenetics in a black Zimbabwean cohort: an observational prospective study.
Pharmacogenomics
July 2023
Department of Genomic Medicine, African Institute of Biomedical Science & Technology, 911 Boronia Township, Beatrice, Zimbabwe.
Article Synopsis
- - A study was conducted to see if clinical guidelines for warfarin dosing could be practically applied to black Zimbabwean patients.
- - Out of 62 patients, 62.90% did not get the recommended starting dose of warfarin according to guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
- - CPIC guidelines consider African-specific genetic variations, making them more suitable for Zimbabwean patients compared to US FDA and Dutch guidelines, which do not account for these variants.
Integrated analysis of clinical and genetic factors on the interindividual variation of warfarin anticoagulation efficacy in clinical practice.
BMC Cardiovasc Disord
May 2023
Department of Pharmacy, The Second Xiangya Hospital, Central South University, No.139, People's Middle Street, Furong District, Changsha City, 40013, Hunan Porv., China.
Aim: The anticoagulation effect of warfarin is usually evaluated by percentage of time in therapeutic range (PTTR), which is negatively correlated with the risk of warfarin adverse reactions. This study aimed to explore the effects of genetic and nongenetic factors on anticoagulation efficacy of warfarin during different therapeutic range.
Methods: We conducted an observational retrospective study aiming at evaluating the impact of clinical and genetic factors on PTTR from initial to more than six months treatment.
Evaluation of a warfarin dosing algorithm including CYP2C9, VKORC1, and CYP4F2 polymorphisms and non-genetic determinants for the Iranian population.
Pharmacol Rep
June 2023
Cellular and Molecular Research Center, Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.
Article Synopsis
- The study aimed to understand how both genetic and non-genetic factors affect warfarin therapy among Iranian patients, leading to the creation of a new dosing prediction algorithm.
- Researchers analyzed 200 patients' DNA and clinical characteristics, finding specific genetic markers and non-genetic factors that influence daily warfarin doses.
- The proposed dosing model explains over half of the variability in warfarin response and offers a more accurate dosing method for Iranian patients compared to existing algorithms.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!